In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.
Understanding the target in context The anticancer drug discovery process often begins with a promising target; however, there are several reasons why the eventual outcome for a particular cancer ...